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Introduction 
Sleep-disordered breathing (SDB), encompassing both obstructive and central sleep apnea, 
occurs frequently in patients with cardiovascular (CV) disease. This thesis is based on sleep 
studies performed in patients with heart failure (HF), and in patients referred to the sleep 
laboratory, with the overall objective of evaluating the association between SDB, HF and CV 
risk factors. 
 
Sleep and its impact on the cardiovascular system 
Sleep is an essential physiologic process for most living organisms [1]. Based on 
electroencephalographic (EEG) monitoring, sleep can be divided into non-rapid eye 
movement (NREM) sleep, which has three defined stages, and rapid eye movement (REM) 
sleep [2] (Figure 1). The number and duration of different sleep stages change throughout a 
person’s lifetime [3].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Example of a hypnogram for adults with awakenings.  
   The thick red horizontal lines show REM sleep.  
   Peaks with thinner lines show short awakenings. 
   W: awake; REM: rapid eye movement; N1,N2,N3: Sleep stages in non-rapid eye 
   movement sleep 
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NREM and REM affect the CV system. NREM sleep is characterized by autonomic stability 
with dominance of the parasympathetic tone, whilst in REM sleep the sympathetic nervous 
system is activated, causing an increase in heart rate and blood pressure (BP) with the 
potential to provoke ischemic episodes and arrhythmias [4].  
Deprivation of sleep, especially selective NREM deprivation, results in impaired cognition 
and vigilance [5;6]. In several studies, short sleep duration has been associated with greater 
adiposity [7;8]. Epidemiological studies suggest that short or long sleep duration, and 
difficulty in remaining sleep, are associated with the development of diabetes [9-11], and 
inadequate or disrupted sleep has been associated with CV disease and hypertension [12-
15]. Unfortunately, most studies have not distinguished between voluntary restriction of time 
asleep and sleep loss or impaired sleep quality caused by pathological conditions like SDB. 
On the basis of the available studies it is not possible to establish a causal link between time 
asleep and CV disease risk. 
 
Obstructive sleep apnea 
Obstructive sleep apnea (OSA) is characterized by repetitive upper airway obstruction during 
sleep (Figure 2). This results in apneas and hypopneas, leading to increased respiratory 
effort, arterial oxygen desaturation and fragmentation of sleep.  
An apnea is the absence of respiration for at least 10 seconds; a hypopnea is a decrease in 
tidal volume of at least 50% followed by ≥ 3% oxygen desaturation [2]. OSA is diagnosed if 
five or more obstructive apneas / hypopneas occur per hour of sleep, as expressed by the 
apnea – hypopnea index (AHI) [16]. AHI cut-off points of 5, 15 and 30 are widely used to 
define mild, moderate and severe OSA, respectively. Although the AHI defines the average 
number of breathing cessations during one night, it does not reflect the duration of apneas or 
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the level of oxygen desaturation, both of which provide important additional information when 
evaluating the severity of SDB.  
 
 
 
Figure 2. Illustration of the upper airway in normal breathing and in obstructive sleep apnea. 
    Adapted from the Mayo Foundation for Medical Education and Research.  
 
 
 
OSA is a relatively common disorder and its prevalence appears to have increased lately. 
[17;18].  In a recent population-based study of adults aged 30 – 65 years in Norway, the 
estimated prevalence of OSA was 16%, with moderate to severe OSA reported in 8% of the 
cohort [19]. Males had a higher prevalence than females (21% vs. 13%), with a similar 
distribution for moderate to severe disease (11% vs. 6%). In the Wisconsin sleep study 
published in 1993, the prevalence of OSA with daytime hypersomnolence (OSA syndrome) 
was estimated to be 4% in men and 2% in women [20].  
Narrowing of the pharyngeal lumen and increased upper airway collapsibility are the main 
pathophysiological features in OSA patients [21]. Body mass index (BMI), male gender, 
increasing age, snoring and neck circumference are associated with the disease [22]. 
Malhotra and White estimated that roughly 70% of OSA patients are obese, and obesity may 
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be the only major modifiable risk factor [23]. The risk of OSA increases with increased body 
weight: a 10% weight gain has been shown to predict a six-fold increase in the likelihood of 
developing moderate to severe OSA [24]. Other risk factors associated with OSA include 
night time nasal congestion, smoking and alcohol consumption before sleep [25].  
Untreated OSA, particularly moderate to severe disease, contributes to worse quality of life, 
worse cognitive performance and excessive daytime sleepiness [26-29].  
 
Co-morbidity in obstructive sleep apnea 
OSA is associated with a number of CV diseases including hypertension, diabetes, coronary 
artery disease, HF and stroke [30]. This association may not be due only to shared risk 
factors, but could also reflect a role of OSA in the etiology of these conditions [25].  
The relationship between OSA and hypertension has been widely investigated. Obstructive 
events during sleep, together with hyperventilation while recovering breath, can result in 
acute changes in BP and heart rate [31]. Despite several coexisting risk factors such as 
obesity, some longitudinal studies have suggested that OSA is an independent risk factor for 
systemic hypertension, although the evidence is inconsistent [32-34]. In the latest European 
guidelines for the management of hypertension, OSA is characterized as a modifiable cause 
of refractory hypertension and should be considered in patients with a non-dipping BP profile 
[35].  
The prevalence of type 2 diabetes is higher in patients with OSA versus non-OSA patients 
even after adjusting for confounding factors [36]. Correspondingly, the prevalence of OSA 
among patients with type 2 diabetes appears to exceed predictions of OSA in the general 
population [37]. OSA is a possible risk factor for developing impaired glucose metabolism 
and type 2 diabetes [38-40], most likely due to deteriorating insulin sensitivity [41]. In recently 
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published analyses from the European Sleep Apnoea Database, increasing severity of sleep 
apnea was associated with higher HbA1c levels in a non-diabetic cohort [42], while OSA was 
associated with an increased risk of concomitant type 2 diabetes and worse diabetes control 
in patients with type 2 diabetes [43]. Furthermore, untreated OSA has been shown to 
increase the incidence of coronary heart disease and HF, CV events and even all-cause 
mortality [44-46].  
 
Central sleep apnea 
Central sleep apnea (CSA) is characterized by insufficient or absent ventilation caused by 
loss of ventilatory drive. It has various manifestations, including Cheyne-Stokes respiration 
(CSR), high altitude-induced periodic breathing and opioid-induced central apnea, arising 
from different pathophysiological mechanisms. Nevertheless, significant CSA is rarely 
recorded in the absence of HF [47]. The most common type of CSA in patients with HF is 
CSR, also referred to as periodic breathing [48;49]. CSR has a characteristic crescendo / 
decrescendo ventilatory pattern with hypopneas or apneas occurring at the nadir of the 
respiratory cycle (Figure 3).  
The appearance of CSR indicates instability of the respiratory control system. In healthy 
subjects, ventilation decreases with sleep onset and the partial pressure of carbon dioxide 
(pCO2) increases, keeping pCO2 above the apnoeic threshold [50]. In HF patients, 
increased venous return in the supine position increases pulmonary capillary wedge 
pressure (PCWP) and lung congestion. This can stimulate pulmonary vagal irritant receptors, 
resulting in reflex hyperventilation [51;52]. Most HF patients with CSA seem to have chronic 
hyperventilation with low pCO2 levels [53;54] In these patients, the carbon dioxide-
dependent apnea threshold seems to be altered [55], facilitating apneas with decreasing 
pCO2. As a result, even a slight increase in ventilation, such as any kind of arousal, can 
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reduce pCO2 below the apnoeic threshold, which results in a central apnea. Apneas leading 
to rising pCO2 induce a secondary hyperventilation response in an attempt to normalize 
pCO2 levels. Additionally, it has been suggested that central pCO2 receptor sensitivity is 
increased, which elicits an inadequate ventilatory response with rising pCO2 [56]. The 
combination of oscillating pCO2 levels and altered chemoreceptor function leads to ongoing 
cycles of hypo- and hyperventilation [57;58]. Another pathophysiological factor that can 
impair the usual feedback mechanism is a prolonged circulation time in HF patients, 
expressed by the correlation between severity of systolic function and Cheyne-Stokes cycle 
length [59].  
Like OSA, CSA with CSR is associated with increased morbidity and mortality, but it remains 
controversial as to whether CSR is simply an epiphenomenon in HF patients or if it 
contributes to morbidity and mortality [60;61].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A 10 minutes trace from a polygraphic recording (Embletta) in a patient with 
Cheyne Stokes respiration.  
Snore = snore signal; SpO2 = oxygen saturation; Flow = flow from nasal air pressure 
transducer; Thorax = thoracic movements measured with respiratory inductance 
plethysmography; Abdomen = abdominal movements measured with respiratory inductance 
plethysmography; Pulse = pulse signal 
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Pathophysiological aspects of obstructive sleep apnea 
Patients with SDB experience a wide range of hormonal, biochemical and hemodynamic 
changes, each of which could affect the heart and the CV system (Figure 4).   
 
Figure 4. Pathophysiological interaction between obstructive / central sleep apnea and 
cardiovascular disease / heart failure. 
 
 
Intermittent hypoxemia, increased respiratory effort, hypercapnia and micro-arousals are the 
main pathophysiological features of OSA [62]. These conditions contribute to sympathetic 
activation [63], expressed by increased sympathetic nerve activity even during daytime 
[64;65], and higher levels of circulating catecholamines [66]. Increased sympathetic 
activation mediated by chemoreflex activation, probably coupled with altered baroreflex 
responsiveness, is considered to be an important contributor to the high prevalence of 
hypertension in OSA [67-69].  
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Several studies have shown left ventricular (LV) hypertrophy to be associated with OSA 
even, in one study, after adjusting for BP levels [70-72]. This appears to result from 
increased LV afterload during obstructive apneas, combined with sympathetic activation and 
intermittent hypoxemia [73]. LV diastolic dysfunction and increased left atrial size, indicative 
of structural myocardial changes, have been detected in otherwise healthy OSA patients 
[74;75].  
Caples and Somers have suggested that recurrent fluctuations in intrathoracic pressure in 
OSA could contribute to chamber enlargement of the thin-walled atria as well as to tissue 
stretch and remodelling at the pulmonary vein ostia, thereby promoting the development of 
atrial fibrillation [76]. Other pathophysiological conditions which could potentially link OSA to 
atrial fibrillation are autonomic imbalance, hypoxia, inflammation and hypertension [77].  
Patients with OSA have a high incidence of serious arrhythmias and sudden cardiac death at 
night, which again may be explained by increased sympathetic activation and hypoxemia 
[78;79].  
During an obstructive apnea, a series of acute hemodynamic changes occur: the attempt to 
breath against the occluded pharynx generates negative intrathoracic pressure, which 
augments right ventricular filling (pre-load) by increasing venous return. At the same time, 
hypoxemia raises pulmonary artery pressure [80], increasing right ventricular afterload. Right 
ventricular distension can cause septal displacement and thereby impairs LV filling [81]. 
Additionally, it is assumed that negative intrathoracic pressure increases LV transmural 
pressure, and hence afterload [82]. Several studies have shown that obstructive apneas or 
their simulation can reduce stroke volume and cardiac output in men [83-86], an effect that is 
more pronounced and sustained in HF patients [87].  
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Mild to moderate chronic pulmonary hypertension has traditionally been associated with 
OSA. However, its prevalence is relatively low and concomitant lung or heart disease is often 
present in this condition [88-90].  
Repetitive desaturations, re-oxygenation and sleep fragmentation appear to trigger systemic 
inflammation, oxidative stress and procoagulant / thrombotic activity, promoting the 
development of atherosclerosis, dyslipidemia and CV disease which are associated with 
OSA [91-93]. However, co-morbidities such as obesity, diabetes, CV disease and smoking 
are all potential confounding factors and causality can not yet be confirmed.   
 
Pathophysiological aspects of central sleep apnea 
The key clinical significance of CSA is its association with increased mortality [48]. Indeed, 
CSA may even be an independent risk factor for all-cause mortality [60].  
Variations in heart rate, oscillating BP and oxygen desaturation occur in CSR [94-96], but no 
additional intrathoracic pressure is generated during a central apnea which affects LV 
afterload. Repetitive nocturnal deprivation of myocardial oxygen has been proposed as a 
mechanism for inducing the progression of chronic HF [97]. It has been shown that HF 
patients with CSR have a higher sympathetic activity, as measured by urinary 
catecholamines, compared to HF patients without CSR [98]. However, increased total body 
and cardiac sympathetic nerve activity in HF patients with CSR, was subsequently found to 
be related to HF severity [99]. In another study, significantly higher urine and plasma 
norepinephrine levels in HF patients with CSR were reduced by continuous positive airway 
pressure (CPAP) therapy [100]. It has been demonstrated that CSR provokes ventricular 
ectopy in HF patients, particularly during the hyperpneic phase [101]. Severe CSR has been 
associated with impaired cardiac autonomic control and increased cardiac arrhythmias in HF 
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patients [102]. Furthermore, CSR seems to be an independent risk factor for malignant 
arrhythmias in this setting [103].  
In summary, the failing heart in patients with CSR is repeatedly exposed to hypoxia, 
oscillating BP and varying heart rate, and possibly to increased sympathetic activity. These 
effects could theoretically contribute to the higher mortality observed in patients with CSR, 
but more evidence is needed to prove causality. 
 
Obstructive sleep apnea and Cheyne-Stokes respiration in heart failure 
The prevalence of SDB is generally higher in HF patients compared with the general 
population, but varies depending on AHI cut-off levels and inclusion criteria. In large-scale 
studies, SDB was present in up to 81% of stable HF patients with reduced ejection fraction 
(EF) [104]. Using an AHI cut-off of ≥ 15, several studies have documented moderate to 
severe SDB in about 50% of patients [105-108]. The prevalence of CSR is associated with 
increasingly symptomatic HF and lower EF [106]. Male gender, age > 60 years, hypocapnia 
during wakefulness and the prevalence of atrial fibrillation may be other risk factors for CSR 
[108]. In HF patients with preserved ejection fraction (HFPEF), up to 69% were found to have 
SDB; the majority had OSA [109;110].  
The relationship between HF and SDB appears to be bidirectional. Pathophysiological 
changes associated with OSA, as described above, contribute to the onset and progression 
of both systolic and diastolic HF. At the same time, the pathophysiological implications of HF 
aggravate OSA and facilitate CSA. HF with fluid overload and overnight redistribution from 
the lower to the upper part of the body can contribute to pharyngeal narrowing, thus 
potentially increasing the severity of OSA, which can be reversed by CPAP [111;112].  
Patients with OSA seem to be more susceptible to pharyngeal obstruction in response to 
fluid redistribution than non-OSA patients [113]. In HF patients, rostral fluid shift may 
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additionally accumulate in the lungs, increasing the PCWP and leading to pulmonary 
congestion, which can provoke hyperventilation that facilitates the development of central 
apneas and CSR [114].  
In HF patients, the type of sleep apnea can change from predominantly obstructive at the 
start of the night to predominantly central events towards the end of the night. This change 
has been associated with a reduction in pCO2, related to overnight deterioration in cardiac 
function as suggested by a prolonged circulation time and an increase in periodic breathing 
cycle length [115]. This generates the hypothesis that not only fluid shift, but in some cases 
also the direct adverse cardiovascular effects of OSA, can lower cardiac output and raise 
PCWP sufficiently to induce CSA [114].  
CSR in HF patients occurs not only at night but also during waking hours [116]. When 
observed during the day, it has been associated with reduced survival [117;118].  
 
Treatment of OSA and CSA 
Management of OSA should include weight reduction, which seems to reduce the severity of 
OSA [24;119] as well as abstinence from alcohol, which predispose to pharyngeal collapse 
during sleep [120].  
The standard treatment for OSA is considered to be CPAP, delivered by a nasal or facial 
mask [121;122]. CPAP keeps the upper airway from collapsing, thus avoiding obstructive 
apneas and hypopneas. In patients with OSA and daytime sleepiness, CPAP significantly 
reduces daytime sleepiness and improves daytime function [123]. The treatment effect is 
well-documented in patients with hypertension [124], and CPAP has also been shown to 
improve insulin resistance and diabetes, especially in patients with severe OSA [125;126].  
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In HF patients, relatively small studies have shown that CPAP treatment can reduce LV 
afterload and heart rate [127], increase left ventricular ejection fraction (LVEF) and decrease 
sympathetic activation [128-130]. Observational studies have demonstrated that CPAP 
treatment was associated with reduced morbidity and mortality in HF patients with OSA 
[131;132], No prospective, randomized trial has yet determined whether CPAP treatment 
influences morbidity or mortality in non-sleepy HF patients.  
The first consideration in HF patients with CSA / CSR should be to optimize HF treatment. 
Adequate drug therapy with beta blockers and diuretics reduces central apnea frequency, 
probably by lowering cardiac filling pressure [51;133]. A meta-analysis has shown that 
cardiac resynchronization therapy, with an implantable device when indicated, is also 
effective in reducing the severity of CSA [134]. Nocturnal oxygen should be considered in 
symptomatic HF patients with CSA but no alternative to ventilator therapy (CPAP / ASV) is 
currently recommended as standard treatment [135].  
Although initial results were promising [136], CPAP treatment in HF patients with CSR failed 
to show a positive impact on mortality in the CANPAP (CANadian continuous Positive Airway 
Pressure) trial [137]. A post-hoc analysis however, revealed a benefit in survival and 
improvement of LVEF in the subpopulation of patients whose AHI was reduced to below 15 
[138].  
A novel ventilator treatment, adaptive servoventilation (ASV) therapy, introduced in 2001, 
was developed specifically to treat CSR [139]. ASV applies anticyclic pressure support 
during periods of periodic breathing in an attempt to maintain a constant breathing volume 
[140]. Compared to CPAP, ASV is more effective in reducing central events and patients 
demonstrate better compliance [141-143]. There is emerging evidence that ASV treatment 
can improve cardiac function and reduce arrhythmic events in HF patients with CSR 
[144;145]. However, there is a need for randomized, controlled trials of ASV therapy in this 
population to examine its effect on morbidity and mortality. 
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Aims of the thesis 
General aims 
• To investigate the association between SDB and CV disease, particularly in HF 
patients. 
Specific aims 
• To investigate the prevalence of SDB in HF patients, focusing on patients with 
preserved LV function (Paper I). 
• To identify clinical predictors of both obstructive and central sleep apnea in HF 
patients (Paper II). 
• To evaluate the individual CV risk profile in patients with SDB (Paper III). 
• To detect undiagnosed CV disease in patients with various degrees of SDB (Paper 
III). 
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Materials and methods 
Study design and population 
This thesis presents material from two clinical studies with a cross-sectional study design. 
Patients studied in Papers I and II were consecutively enrolled from the outpatient HF clinic 
of Lovisenberg Diakonale Hospital, Oslo, Norway. The HF clinic was established in order to 
give optimal medical treatment to patients with HF, and has specially-trained nurses working 
in close cooperation with cardiologists.  It is included in the Norwegian Heart Failure Registry 
[146]. The majority of patients are referred from the cardiology department at Lovisenberg 
Hospital, with a minority referred directly from their primary care physicians. The diagnosis of 
HF is based on clinical signs and symptoms, measurement of N-terminal prohormone brain 
natriuretic peptide (NT-proBNP), and assessment of LV function, according to current HF 
guidelines [147;148].  
Papers I and II included patients aged 18 to 80 years who had clinically stable HF with fully 
up-titrated HF medication as recommended in the HF guidelines. Patients were excluded if 
they had been hospitalized for any reason or had needed intravenous diuretics within the 
previous six weeks. Further exclusion criteria were myocardial infarction or stroke within the 
previous three months, and severe or very severe chronic obstructive pulmonary disease 
(COPD) (stage III and IV) based on lung function according to the Global Initiative for 
Chronic Lung Disease [149]. The inclusion period was between June 2006 and December 
2008. In total, 120 patients met the inclusion criteria. Five patients refused to participate 
because of the inconvenience, such that 115 HF patients were enrolled in the study. 
Paper III included patients from the Sleep Laboratory at Lovisenberg Diakonale Hospital, 
recruited during the period from October 2009 to March 2010. Patients were referred for an 
evaluation of SDB by their general practitioners or an Ear, Nose and Throat specialist. 
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Exclusion criteria were known sleep apnea, or cases in which the sleep study was being 
undertaken for therapeutic purposes. In total, 255 subjects were enrolled and all participants 
gave written informed consent.  
The study protocols were reviewed and approved by the Regional Ethics committee and the 
Norwegian Data Inspectorate.  
 
Study procedures 
All HF patients in Paper I underwent an overnight polygraphy (PG) (Embletta, ResMed, 
Norway) which was performed unattended at home. Nasal airflow, thoracic and abdominal 
movements, pulse oximetry, body position and a three-channel electrocardiogram (ECG) 
were recorded continuously. In Paper III, the Reggie system (Camtech, Norway), which has 
an additional esophageal catheter that indirectly measures intrathoracic pressure [150], was 
used in addition to the Embletta. Thirty-four out of 255 patients in Paper III had an 
inconclusive PG or were unable to complete an unattended PG and were therefore 
diagnosed with an in-hospital polysomnography (PSG) (Embla, ResMed, Norway). The PSG 
additionally included a six-channel EEG, a two-channel electrooculogram, a submental 
electromyogram (EMG) and an EMG from both legs. 
Data were blinded and scored at the Lovisenberg Sleep Laboratory by a qualified sleep 
specialist using a modified version of the 2007 American Academy of Sleep Medicine manual 
for the scoring of sleep and associated events [2]. An obstructive apnea was defined as ≥ 10-
second pause in respiration with ongoing respiratory effort. An obstructive hypopnea was 
defined as a minimum 50% reduction in airflow with either a ≥ 3% oxyhemoglobin 
desaturation or an arousal. Arousals were diagnosed by EEG in a PSG or were classified as 
a presumed arousal in the PG using heart rate response as a surrogate for arousal from 
sleep. A central apnea was defined as ≥ 10-second pause in respiration without thoracic and 
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abdominal effort. The AHI was calculated based on actual sleep time (PSG) or analyzed time 
(PG).  
The diagnosis of SDB was made if the patient had ≥ 5 apnea / hypopnea events per hour of 
sleep. SDB severity was graded according to guideline recommendations [16] and our 
clinical routine as mild (AHI 5 – 14.9), moderate (AHI 15 – 29.9) and severe (AHI ≥ 30). 
CSR was diagnosed if the patient had central AHI ≥ 5 and at least three consecutive cycles 
of crescendo and decrescendo changes in breathing amplitude or the cyclic crescendo / 
decrescendo pattern lasted for at least 10 consecutive minutes [2].  
Patients with both obstructive and central apneas were classified according to the dominating 
respiratory sleep pattern. 
 
Evaluated parameters 
Demographic and co-morbidity data were extracted from the Norwegian Heart Failure 
Registry [146] and from patient records. Quality of life was measured using The Minnesota 
Living with Heart Failure Questionnaire [151]. Daytime sleepiness was evaluated with the 
Epworth Sleepiness Scale (ESS) [152]. All patients in Paper I had a two-dimensional 
echocardiographic assessment of LVEF. Patients with EF ≥ 45% were considered to have 
preserved EF. 
Blood samples analyzing hemoglobin, CRP, creatinine, cholesterol, triglycerides, glucose, 
HbA1c and NT-proBNP were obtained the morning after the sleep study. 
Office BP measurements in Paper III were performed with a sphygmomanometer on the 
upper arm using the standard technique [153].  A minimum of three BP measurements were 
obtained and the average of three multiple readings was used for statistical purposes.  
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A 12-lead ECG was performed on the same day. The ECG was analyzed manually by a 
single, blinded observer as described in Paper III. 
In order to assess the individual CV risk, the Framingham general CV disease risk score was 
calculated for each patient based on the following parameters: age, gender, systolic BP, 
total-cholesterol, HDL-cholesterol, hypertension treatment, current smoking and diabetes. 
The Framingham general CV disease risk score is expressed as the 10-year risk for coronary 
death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, transient 
ischemic attack, peripheral artery disease and HF [154;155].  
Patients with a fasting glucose > 5.6 mmol/l and / or HbA1c > 5.7% were requested to 
perform a two-hour oral glucose tolerance test (OGTT) with a 75 g glucose load. Patients 
with a two-hour plasma glucose value of between 7.8 and 11.1 mmol/l were defined as 
having impaired glucose tolerance. Diabetes mellitus was diagnosed if fasting plasma 
glucose was ≥ 7 mmol/l and / or HbA1c ≥ 6.5 %, or the 2-hour plasma glucose in the OGTT 
was ≥ 11.1 mmol/l. Patients with a fasting glucose between 5.6 and 6.9 mmol/l and a normal 
OGTT were classified as impaired fasting glucose according to updated diabetes guidelines 
[156].  
 
Statistical analyses 
Statistical analyses were performed using SPSS software version 17.0 and 18.0 (SPSS Inc. 
Chicago, IL, USA). Continuous data were presented as mean ± standard deviation or as 
median values with 25th and 75th percentiles if distribution was non-normal. Differences 
between groups were assessed using the independent samples t-test for variables with 
approximately normal distribution, and the Mann-Whitney rank sum test for non-normal 
continuous variables. Categorical data were listed as frequencies and percentages and were 
compared using the Chi-square test. Both bivariate and multivariate analyses (logistic 
 24 
regression) were applied to detect variables predicting sleep apnea. Linear regression 
analysis was used when comparing CV disease risk in different AHI classes, with log of the 
Framingham score as dependent variable. The log transformation was performed to fulfil the 
linearity assumption in linear regression analysis. 
All tests were two-tailed and findings with p < 0.05 were considered statistically significant.  
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Summary of results 
Paper I 
High prevalence of sleep apnea in heart failure outpatients: even in patients 
with preserved systolic function 
We investigated the prevalence of SDB in a cohort of HF outpatients (n = 115). Patients were 
clinically stable and receiving fully up-titrated HF medication. Sixty-two percent had reduced 
EF, and 38% had HFPEF. The overall prevalence of SDB was 81% (AHI ≥ 5). Moderate to 
severe SDB (AHI ≥ 15) was present in 52% of cases (Figure 5). We found no differences in 
EF, quality of life or sleepiness between patients with and without SDB. 
HFPEF patients showed almost the same prevalence of SDB as the group with reduced EF 
(80% vs. 82%). In HFPEF patients, however, OSA (62%) was far more frequent than CSA 
(18%). Compared to HFPEF patients without OSA, HFPEF patients with OSA had a higher 
BMI (32 ± 5.8 vs. 27.9 ± 4.1, p = 0.02) and a higher proportion had hypertension (74% vs. 
35%, p = 0.01). 
Figure 5. Prevalence of SDB in a stable HF population. N = 115 
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Paper II 
Clinical predictors of sleep apnea in heart failure outpatients 
In this paper, we aimed to identify clinical predictors of moderate to severe SDB in HF 
patients. The patient cohort was identical to Paper I. Fifty-two percent of patients had AHI ≥ 
15. In the multivariable logistic regression model, we found that BMI ≥ 30 kg/m² was the only 
independent predictor of moderate to severe SDB (p = 0.008). Hypertension was a predictor 
for OSA (p = 0.02), while hemoglobin ≥ 15 g/dl was associated with CSA (p = 0.002). 
Quality of life and level of sleepiness were not significantly associated with SDB. Patients 
with mild to moderate COPD were less likely to have SDB compared to patients without 
COPD (p = 0.002).  
 
 
Paper III 
High cardiovascular risk profile in patients with sleep apnea 
We investigated the individual CV risk profiles of patients with SDB and the prevalence of 
premature and undiagnosed disease in this group. The study cohort included 255 patients 
referred to the Sleep Laboratory for a sleep evaluation, of whom 190 (75%) were diagnosed 
with SDB. All patients had predominantly OSA (AHI ≥ 5). 
Patients with moderate to severe SDB (AHI ≥ 15) had a higher prevalence of known heart 
disease and hypertension compared with patients without sleep apnea. In addition, patients 
with moderate to severe SDB had a significantly higher fasting glucose, HbA1c, cholesterol 
to HDL-cholesterol ratio and CRP. 
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Patients with SDB had a higher median Framingham risk score than patients without SDB. 
Compared to patients without SDB, patients with severe SDB had a significantly higher 
Framingham score [RR 1.60 (95% CI: 1.26 – 2.05, p < 0.001)], adjusted for age and gender, 
representing a 60% increased risk of developing CV disease over the next 10 years. 
Among participants without known hypertension, 114 were diagnosed with SDB. In this 
group, only 11% had optimal BP, 44% had pre-hypertension and 45% had significantly 
elevated BP. These results remained consistent for all AHI classes (Figure 6).  
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Figure 6. Blood pressure measurements in SDB patients without known hypertension 
Optimal:  Systolic < 120 mmHg and diastolic < 80 mmHg 
Normal:  Systolic 120 – 129 mmHg or diastolic 80 – 84 mmHg 
High-normal: Systolic 130 – 139 mmHg or diastolic 85 – 89 mmHg 
High:  Systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg 
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Among patients without known diabetes, 171 were diagnosed with SDB. In this “non-diabetic” 
group, 48% had pathological glucose disposal comprising impaired fasting glucose in 38% of 
patients and impaired glucose tolerance in 9% of patients. One patient met the diagnostic 
criteria for diabetes mellitus (Figure 7). Within the “non-diabetic” group of patients who had 
moderate to severe SDB, 57% had pathological glucose disposal.  
Twenty percent of SDB patients without known heart disease had significant ECG changes. 
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Figure 7. Glucose disposal in 171 “non-diabetic” patients with SDB  
IFG: Impaired Fasting Glucose, IGT: Impaired Glucose Tolerance, D.m.: Diabetes mellitus 
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Discussion 
Attention has recently focussed on SDB and its impact on CV disease, especially in patients 
with HF [30;82;157]. In this thesis we have demonstrated a high prevalence of SDB in HF 
outpatients. Furthermore, we have explored possible clinical predictors that could be used to 
select patients for referral to a sleep specialist. Moreover, we found that subjects with SDB 
diagnosed at the Sleep Laboratory have a significantly higher 10-year risk of developing CV 
disease compared to subjects without SDB. Patients with SDB also have a high prevalence 
of unidentified medical conditions including elevated BP, pathological glucose disposal and 
ECG changes.  
 
Sleep studies  
All our patients in the HF cohort were tested at home with PG, measuring nasal air flow via a 
nasal pressure transducer, thoracic and abdominal movements (respiratory inductance 
plethysmography), pulse oximetry and body position. A PSG is an overnight study, usually 
performed at the hospital, which in addition assesses sleep, wakefulness and muscle activity 
by using EEG, oculography and myography. The PSG is considered the gold standard for 
diagnosing sleep disorders [16], even though it is time-consuming, relatively expensive and 
often unavailable outside specialist centres.  
In terms of scoring and calculating sleep indices, the main advantage of PSG is that the EEG 
recording allows an exact determination of sleep time and respiratory arousals. Without 
direct information on sleep, the calculated indices in a PG can be underestimated compared 
to a PSG. If sleep disorders other than moderate to severe OSA or CSA are suspected, or if 
the patient shows symptoms of daytime sleepiness or snoring and has a negative PG, a 
complete sleep study with PSG should be considered [158].  
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In Paper III, 34 out of 255 patients completed a PSG. The distribution of AHI groups was 
similar to PG patients, with a slightly higher percentage of patients in the severe SDB group 
(no SDB 18%, mild 29%, moderate 21%, severe 32%). A separate statistical analysis 
excluding PSG patients did not show any significant difference to the main results.  
Because of the high number of patients with suspected breathing disorders at night, 
especially patients with CV disease, clinicians need a relatively simple and practice means to 
diagnose SDB. In several studies, home-based cardiorespiratory PG has been shown to 
diagnose breathing disorders satisfactorily during sleep compared to a PSG, and with lower 
costs [159-164]. Additionally, it could be available at most hospitals, enabling more patients 
to be studied. 
Even simpler devices have been tested [165;166] and in the future may be adequate to 
screen patients at risk in a primary care setting before referral to a sleep specialist.  
 
Study population 
In Papers I and II, all patients were consecutively enrolled from the outpatient HF clinic at 
Lovisenberg Diakonale Hospital. They were referred either by their primary care physician or 
by the Medical Department at the hospital. The relatively high prevalence of SDB in our 
cohort was consistent with large-scale studies by Oldenburg and Bitter [106;109], even 
without the potential referral bias that tertiary centers in Germany may experience, where 
often only patients with more severe or complex disease are transferred to university 
hospitals. 
The use of beta blockers has previously been shown to have a negative correlation with the 
prevalence of SDB [133;167;168]. In our study, we had a higher percentage of beta-blocker 
and angiotensin-converting-enzyme inhibitor / angiotensin receptor blocker usage compared 
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to prevalence studies from the USA and France [104;169]. This implies that SDB is a 
common condition even in a relatively unselected and well-treated HF population.  
In Paper III we included patients referred to the Sleep Laboratory by their primary care 
practitioner or Ear, Nose and Throat specialist for an evaluation of SDB. Since at the time of 
the study Lovisenberg Diakonale Hospital was the only Sleep Laboratory in Oslo, we assume 
that there is no relevant referral bias in our study and the present data should be 
representative of a typical SDB population.  
 
Sleep-disordered breathing in heart failure  
The main finding in Paper I was a high prevalence of SDB in clinically stable HF outpatients 
treated at the HF clinic. Most prevalence data published previously were based on HF 
patients with reduced EF [104;106;169;170]. Our study included HF patients regardless of LV 
function. Sleep data on HF patients with preserved systolic function are rare. Chan et al. 
performed sleep studies on 20 patients with isolated diastolic dysfunction and found a SDB 
prevalence of 55%, using AHI > 10 as a cut-off value [110]. The first large-scale prevalence, 
study including 244 HFPEF patients, was published in 2009 by Bitter et al [109]. They 
described a SDB prevalence of 69.3%, based on an AHI cut-off value of ≥ 5, which is close 
to the prevalence observed in our cohort. As in our study, the majority of these patients had 
OSA.  
OSA is considered an important risk factor for hypertension [171]. In hypertensive patients, 
micro- and macrovascular changes can lead to structural damage in the heart and may 
cause ventricular stiffness and LV hypertrophy, resulting in diastolic HF [172]. But impaired 
diastolic function has also been directly associated with OSA [173]. As described earlier, 
several pathophysiological mechanisms have been identified that could contribute to the 
relationship between OSA and morphological and functional changes in the myocardium.  
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In several studies, OSA was associated with atrial fibrillation [174;175]. It is unclear whether 
atrial fibrillation contributes directly to HFPEF but, notably, it occurs in two-thirds of these 
patients and confers a poor prognosis [176].  
Randomized clinical trials investigating the effect of CPAP treatment on morbidity and 
mortality in HFPEF patients with OSA are still required. However, CPAP has been shown to 
lower BP in patients with OSA [124] and may lower the recurrence of atrial fibrillation after 
cardioversion and catheter ablation (pulmonary vein isolation) [177-179]. While further 
research is necessary to define effective strategies for medical treatment of HFPEF [180], it 
seems reasonable to treat co-morbidities such as hypertension and OSA. 
In previously published studies, CPAP treatment of HF patients with OSA and reduced EF 
improved EF and quality of life [128;129;181]. In patients who had predominantly CSA with 
CSR, treatment with ASV appeared superior to CPAP in reducing the AHI [139] and may 
improve HF symptoms and cardiopulmonary performance [182;183]. However, results from 
randomized controlled trials are required to assess the effect of ventilation therapy on 
morbidity and mortality in HF patients with CSR.  
In our opinion, the high prevalence of SDB in HF patients and the promising results observed 
positive airway pressure treatment indicate that sleep apnea should be considered as part of 
the diagnostic routine when managing patients with HF. 
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Clinical predictors of sleep-disordered breathing in heart failure  
In Paper II, BMI ≥ 30 kg/m² was shown to be an independent predictor of moderate to severe 
SDB in HF patients. Patients with OSA had a slightly higher BMI than patients with CSA but 
the difference was not statistically significant. Sin et al. [108] found in their cohort that BMI 
was a risk factor only for OSA. As previously mentioned, HF patients with reduced EF have a 
high prevalence of both OSA and CSA with CSR. Additionally, mixed sleep apnea – where 
central apneas are followed by airway obstruction in the same apnoeic event – can occur in 
this group [62]. Instances where obstructive respiratory events lead to central respiratory 
events and vice versa, as well as a shift in the predominant type of SDB, were observed 
[115;184;185]. Thus, a significant overlap between OSA and CSA seems to be present in HF 
patients.  
We assume that the overlap between OSA and CSA explains why obesity with a BMI cut-off 
of 30 kg/m² emerged as a marker to predict moderate to severe SDB of all types in our study. 
Daytime sleepiness, as measured with the ESS, could not predict SDB in our cohort of HF 
patients. As reported in previous studies, hypersomnolence is usually not found in HF 
patients despite significantly reduced sleep time and poorer objective sleep quality [186-188]. 
This can partly be explained by increased daytime sympathetic activity [189]. Based on these 
findings, sleepiness (and especially ESS) cannot be recommended as a screening tool for 
SDB in HF patients. 
Hypertension was a predictor for OSA in our HF patients. In epidemiological, cross-sectional 
and longitudinal studies, OSA was a risk factor for hypertension [34;190-192]. A high 
prevalence of OSA was found in hypertensive patients, particularly for drug-resistant 
hypertension [193;194]. In addition to the increased risk of becoming hypertensive, elevated 
BP appears more difficult to treat with coexisting OSA.  
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Hypertension is strongly related to LV hypertrophy but the mechanisms are complex and 
multifactorial [195]. We know from longitudinal studies that hypertension predisposes 
patients to HF [196]. LV mass is higher in hypertensive patients with a non-dipper BP profile 
than in those with a nocturnal BP reduction of > 10%  [197]. Unfortunately, sleep data were 
lacking in this cohort. Several studies have shown that both systolic BP and OSA are 
associated with LV hypertrophy, although there is some conflicting data as to whether this 
association is dependent or not [70-72;197-199].  
As discussed above, OSA is not only a risk factor for high BP, but may also contribute 
directly to deteriorating cardiac function in patients with hypertension. Therefore we suggest 
that HF patients with hypertension should be considered for sleep studies to rule out OSA as 
an underlying co-morbidity. 
Hemoglobin ≥ 15 g/dl was associated with CSA in our cohort. In a sub-study of the ELITE II 
trial, polycythemia with hemoglobin > 15 g/dl was associated with significantly increased 
mortality [200]. The authors argued that polycythemic HF patients are at particular risk of 
thrombotic events and detrimental effects caused by the generation of oxygen-derived free 
radicals, but the reason for increased mortality in this polycythemic HF cohort remains 
unclear. Nocturnal hypoxia in HF patients with central sleep apnea has been shown to be a 
stimulus for erythropoietin production [201], potentially leading to higher hemoglobin levels. 
Patients with CSA typically suffer from more severe HF and may therefore receive more 
diuretic therapy than patients with OSA, which can contribute to a further increase in 
hemoglobin. Hypothetically, polycythemic patients in the ELITE II trial could have had a high 
prevalence of CSA, which would have been a possible explanation for polycythemia and an 
additional marker for increased mortality. Further studies are needed to investigate if there is 
an association between CSA and mortality in HF patients with polycythemia. 
COPD is a relatively common concomitant disease in HF [202]. In our cohort, mild to 
moderate COPD was found to be an independent predictor for no SDB. This finding cannot 
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be compared to previous studies because COPD of any severity was an exclusion criteria in 
recently published studies of SDB prevalence in HF patients [104;106;169]. COPD in 
subjects with OSA seems to be as frequent as in the general population but no association 
has been shown between these two disorders [203;204]. To our knowledge, there are no 
data available regarding the coexistence of CSA with CSR and COPD.  
A possible explanation for our finding of a negative association between COPD and SDB 
might be that COPD patients do not reach pCO2 levels that are low enough to initiate CSR 
cycles. Presumably, there is also an altered chemo-receptor system in this group. Further 
studies are needed to support this contention. 
 
Cardiovascular risk in patients with sleep-disordered breathing 
In Paper III, the Framingham general CV disease risk score was significantly higher in 
patients with SDB compared to the group without SDB. Adjusted for age and gender, 
patients with severe SDB had a 60% increase in 10-year CV disease risk. As discussed 
above, SDB is associated with a number of conditions and diseases which can cause and 
accelerate the development of CV disease. Hypertension [34;192;205], insulin resistance / 
diabetes and altered lipid metabolism [206-208] are particularly noteworthy in this context 
and account for a higher Framingham risk score. Finally, a high prevalence of smoking (up to 
30% in patients with severe SDB) contributed to the higher Framingham risk score and might 
concurrently increase the risk of OSA [209].  
A relatively high percentage of SDB patients included in our study – up to 47% of those with 
severe SDB – were treated for hypertension. This is consistent with results from a study by 
Lavie et al. [171]. Additionally, the majority of patients without known hypertension in our 
cohort had elevated BP. Bearing in mind that masked hypertension seems to be frequent in 
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OSA [210], patients diagnosed with OSA should be considered for close follow-up with 
repeated BP measurements. 
The prevalence of known diabetes among our patients with SDB was as high as 15% in the 
subpopulation with severe SDB, which is slightly higher than in the Wisconsin Sleep Cohort 
[36]. Additionally, however, 48% of “non-diabetics” had impaired glucose metabolism and 
one patient met the criteria for diabetes. Impaired fasting glucose and impaired glucose 
tolerance put these patients at high risk for developing type 2 diabetes, and increased their 
CV risk [211]. Prospective studies are needed to investigate whether CPAP treatment can 
prevent the development of diabetes and reduce the overall CV risk in this group. 
Among SDB patients without known heart disease and a mean age of 50 years, significant 
ECG changes were observed in 20% of cases. The changes were predominantly signs of LV 
hypertrophy and ST-T changes, possibly reflecting structural heart damage. These were also 
the main ECG findings in the Wisconsin Sleep Cohort study [212]. In a large population-
based sample from the same age group (45 – 55 years), including patients with known 
coronary heart disease, major ECG changes were seen in < 5% of cases and minor changes 
in up to 8.5% [213].  
Due to the frequency of ECG findings in OSA patients – even in those without known heart 
disease – we suggest that patients with SDB should be considered for ECG screening and 
referred to a cardiologist if ECG changes are present.  
In 2008, the American Heart Association / American College of Cardiology stated that 
available evidence points to a CV benefit for CPAP treatment in OSA [157]. The main goal of 
the report was to improve the management of SDB in patients with CV disease. On the other 
hand, it seems equally important to identify and treat all medical co-morbidities in patients 
with SDB in order to minimize the risk of CV-related death. Thus, appropriate screening 
routines to detect concomitant CV disease in patients diagnosed with SDB are advisable. 
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Limitations 
The main limitation of Papers I and II is the relatively small number of patients, especially in 
subgroup analyses. This applies primarily to our analyses of the possible impact of COPD on 
SDB and the significance of hemoglobin levels in HF patients with CSA, which need to be 
confirmed in larger studies. The mean age of patients with SDB was 62 years, mainly due to 
exclusion of patients > 80 years. Our results cannot, therefore, be extrapolated for patients 
over 80 years of age.  
 
 
Conclusions 
This thesis shows that:  
• SDB is highly prevalent in HF patients. 
• SDB, and in particular OSA, is a common and probably important co-morbidity in 
HFPEF patients. 
• In HF patients, BMI ≥ 30 kg/m² is a predictor of moderate to severe SDB of all types, 
and could be used to stratify HF patients before referral to a sleep specialist. 
• Patients with severe SDB have a 60% increase in 10-year CV disease risk, measured 
by the Framingham general CV disease risk score. 
• Undiagnosed hypertension, pathological glucose disposal and ECG changes are 
highly prevalent in patients with SDB. 
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Future Perspectives 
SDB is highly prevalent among HF patients and represents a diagnostic and therapeutic 
challenge for HF management. In order to decrease the number of undiagnosed cases of 
SDB, sleep apnea screening could be considered at primary care level and at HF clinics. 
This could improve the diagnosis of SDB and also reduce the number of normal sleep 
studies performed at sleep laboratories. 
Knowledge about the impact of treating OSA with CPAP, especially CSR with ASV or other 
treatment options, is still limited in patients with HF. Long-term studies investigating the 
prognostic value of SDB treatment are required in this population, with the ultimate aim of 
identifying subgroups who would obtain the most benefit from intervention.  
It also remains to be established whether it is reasonable to use AHI as the main treatment 
indicator or if different markers for hypoxia / level of desaturation should also be employed.    
In the case of CSA with CSR, the results from two large randomized controlled trials are 
expected shortly, and will illuminate the role of ASV treatment in HF patients with reduced 
EF.  
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